Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer

Punita Dhawan,1 Amar B. Singh,2 Natasha G. Deane,1,3 YiRan No,1 Sheng-Ru Shiou,1 Carl Schmidt,1 John Neff,1 M. Kay Washington,4 and R. Daniel Beauchamp1,5,6

1Surgical Oncology Research Laboratories, Department of Surgery, 2Department of Medicine, 3Department of Pathology, 4Department of Cell & Developmental Biology, and 5Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Disruption of the cell-cell junction with concomitant changes in the expression of junctional proteins is a hallmark of cancer cell invasion and metastasis. The role of adherent junction proteins has been studied extensively in cancer, but the roles of tight junction (TJ) proteins are less well understood. Claudins are recently identified members of the tetraspanin family of proteins, which are integral to the structure and function of TJs. Recent studies show changes in expression/cellular localization of claudins during tumorigenesis; however, a causal relationship between claudin expression/localization and cancer has not been established. Here, we report an increased expression of claudin-1 in human primary colon carcinoma and metastasis and in cell lines derived from primary and metastatic tumors. We also report frequent nuclear localization of claudin-1 in these samples. Genetic manipulations of claudin-1 expression in colon cancer cell lines induced changes in cellular phenotype, with structural and functional changes in markers of epithelial-mesenchymal transition. Furthermore, we demonstrate that changes in claudin-1 expression have significant effects on growth of xenografted tumors and metastasis in athymic mice. We further provide data suggesting that the regulation of E-cadherin expression and β-catenin/Tcf signaling is a possible mechanism underlying claudin-1-dependent changes.

Introduction

Cell-cell adhesion in epithelial cell sheets is maintained mainly through adherens junctions (AJs) and tight junctions (TJs). AJs have been a major focus of cancer studies, and expression and/or integrity of several AJ components, catenins (α, β, γ, and E-cadherin in particular), are altered or dysregulated in various carcinomas (1–4). Activation of the Wnt signaling cascade, due either to inactivating mutations in the adenomatous polyposis coli (APC) or activating mutations in the gene encoding β-catenin, is observed in the majority of colorectal cancers (5–9).

In contrast to the roles of AJs proteins, the role of TJ proteins in cancer is less well understood. TJs are the most apical cell-cell contacts and are important for barrier function in epithelial and endothelial cells (10, 11). A number of integral membrane proteins associated with the TJ have been identified during recent years, including occludin (12), junctional adhesion molecule (13), and the claudin family consisting of at least 24 members (14). Tumor cells, particularly in those cancers that manifest high metastatic potential, often exhibit loss of functional TJs. For example, levels of zona occludens 1 (ZO-1), ZO-2, and occludin are decreased during tumor formation and metastasis (15, 16).

The role of claudins in cancer has not been clearly defined. For instance, while claudin-7 has been found to be decreased in invasive ductal carcinomas of the breast (17), levels of claudin-3 and -4 are frequently elevated in various cancers, including pancreatic adenocarcinoma and ovarian cancer (18, 19). Claudins encode proteins with 4 transmembrane domains, and their N- and C-terminal ends are located in the cytoplasm. Claudin family members interact with each other through homo- and heterophilic interactions. In addition, the C-terminal domain of claudins also serves as a binding site for interaction with a complex set of proteins including a number of PDZ domain proteins—ZO-1, ZO-2, ZO-3, multi-PDZ domain protein 1 (MUPP1)—that are potentially involved in signaling (20, 21). Furthermore, stimulation by growth factors (EGF and TGF-β) regulates the expression of various claudins, but the significance of this regulation is as yet unclear (22, 23). It is of interest that claudin-1, -2, -3, and -5 have been reported to recruit E-cadherin to the cell membrane through the PDZ domain protein 1 (MUPP1)—that are potentially involved in cell adhesion—promoting the activation of pro–MMP-2 (24, 25), which suggests potential involvement in invasion and metastasis. Claudin-1 was also recently identified as a probable target of β-catenin/Tcf signaling, which supports a potential role for claudin-1 dysregulation in colorectal carcinogenesis (26). Based on these studies, we hypothesized that claudins have a causal role in the process of cellular transformation and invasion.

In the present study, we report increased expression of claudin-1 in human colon cancers, with mislocalization from the cell membrane to the cell nucleus and cytoplasm. Metastatic colon cancer cells expressed the highest levels of claudin-1 and exhibited the highest rate of cellular mislocalization. Using genetically manipulated colorectal cancer cell lines as tools for in vitro and xenograft tumor models, we demonstrate a role for claudin-1 in the regulation of cellular transformation, tumor growth, and metastasis.

Results

Claudin-1 expression increases with the progression of colon carcinoma and metastasis. Paraffin-embedded sections of normal, primary, and metastatic human tumor specimens from 25 individual patients were examined for claudin-1 immunoreactivity. In contrast to normal colonic mucosa, where the staining was restricted to the cell

Nonstandard abbreviations used: AJ, adherens junction; APC, adenomatous polyposis coli; EMT, epithelial-mesenchymal transition; FSP1, fibroblast-specific protein-1; MTT, tetrazolium salt; NLS, nuclear localization signal; RIE cell, rat intestinal epithelial cell; siRNA, small interfering RNA; TJ, tight junction; ZO-1, zona occludens 1.

Conflict of interest: The authors have declared that no conflict of interest exists.

membrane and stained laterally rather than apically, colon carcinomas and metastatic lesions showed enhanced and nonfunctional claudin-1 staining, localized largely in the nucleus and cytoplasm (Table 1 and Figure 1, A–I). In addition to being mislocalized, claudin-1 immunoreactivity was consistently more intense and present in a higher percentage of cells from primary colon adenocarcinoma and further from metastatic lesions than normal colon epithelial cells (P < 0.0001, for cytoplasmic and nuclear staining). Interestingly, nuclear staining of claudin-1 was observed in 58% of liver metastases (7/12) and in 35% of lymph node metastases (3/13) but not in normal colon epithelial cells (0/25).

Immunoblotting was performed using total cell lysates from colon cancer cell lines, including HCT116, HT29, SW480, and SW620, and from human tissues (matched normal mucosa, primary colon carcinoma, and liver metastasis samples from 3 patients) using claudin-1–specific antibody (Figure 1J, upper panel). Nontransformed rat intestinal epithelial (RIE) cells were included as an example of noncancerous intestinal epithelial cells. Claudin-1 was undetectable in the RIE cells and YAMC cells (an immortalized but nontransformed mouse colonocyte cell line; data not shown). In contrast, claudin-1 was expressed in SW480, HT29, and SW620 cells, with the highest expression in the metastatic colon cancer cell line SW620. Interestingly, each of these 3 cell lines carries an APC mutation, while RIE and HCT116 express wild-type APC. However, the HCT116 cells express a mutant, activated form of β-catenin.

The level of claudin-1 expression was also higher in primary human colon tumor lysates and lysates from metastatic lesions than in adjacent normal tissue (Figure 1J, lower panel). Semiquantitative RT-PCR analysis of claudin-1 mRNA expression further supported this observation, showing 1.4-fold higher expression of claudin-1 in SW620 cells compared with HT29 and SW480 cells (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI24543DS1). No mRNA expression for claudin-1 was detected in RIE or HCT116 cells, which also supports the data from the immunoblot analysis (Figure 1J, upper panel). Another claudin isoform, claudin-7, was expressed in the RIE cells, and it was expressed less abundantly in colon cancer tissue lysates and cell lines than was claudin-1.

Immunofluorescence studies using SW620 cells showed that claudin-1 was localized predominantly in the cell nucleus and in the cytoplasm, in contrast to claudin-4, which was predominantly localized on membrane (Figure 1, K–M). As expected, SW620 metastatic cells expressed low levels of E-cadherin. Immunofluorescence colocalization studies with the nuclear-specific marker DAPI along with claudin-1 antibody confirmed that claudin-1 was predominantly localized in the nucleus in SW620 cells (Figure 1, N–P).

To confirm our observations from immunofluorescence studies, we prepared cytoplasmic, nuclear, and membrane-specific fractions as described in Methods and immunoblotted them with an anti–claudin-1 antibody. The nuclear and cytoplasmic expression of claudin-1 was greater in SW620 cells than in SW480 cells, with a concomitant decrease in the membrane fraction. No claudin-1 expression was detected in RIE or HCT116 cells in either the cytoplasmic or nuclear-specific fractions (Figure 1Q). To ensure that the observed nuclear signal of claudin-1 was not simply a contamination from cytoplasmic extracts and vice versa, we stripped these blots and reprobed them with α-tubulin (cytoplasmic marker) or hnRNP70 (nuclear marker). No α-tubulin expression was detected in nuclear fractions, and no hnRNP70 expression was detected in cytoplasmic fractions or in membrane fractions, even at prolonged exposures, which confirmed the specificity of the cellular fractions.

It was interesting that all the colon cancer cell lines with increased expression of claudin-1 are known to carry an APC mutation, a well-known initiating factor of carcinogenesis in the colon. Therefore, to confirm that claudin-1 is indeed a target of the APC/β-catenin pathway in vivo, we performed immunohistochemical analysis for claudin-1 in adenomas from ApcMin/+ mice. In results supporting our hypothesis, claudin-1 protein levels were not only highly elevated, but expression was predominantly mislocalized from the membrane to the nucleus and cytoplasm in the intestinal adenomas of ApcMin/+ mice (Figure 1, S–U). In the normal-

---

### Table 1

 Claudin-1 immunolocalization in colonic mucosa and colon carcinoma

<table>
<thead>
<tr>
<th>Scoring for claudin-1 immunostaining</th>
<th>0</th>
<th>1+</th>
<th>2+</th>
<th>3+</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Claudin-1, normal (n = 25)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nucleus</td>
<td>25 (100%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0/25 (0%)</td>
</tr>
<tr>
<td>Cytoplasmic</td>
<td>25 (100%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0/25 (0%)</td>
</tr>
<tr>
<td>Membranous</td>
<td>6 (24%)</td>
<td>7 (29%)</td>
<td>6 (24%)</td>
<td>6 (24%)</td>
<td>19/25 (76%)</td>
</tr>
<tr>
<td><strong>Claudin-1, primary tumor (n = 25)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nucleus</td>
<td>23 (92%)</td>
<td>2 (8%)</td>
<td>0</td>
<td>0</td>
<td>2/25 (8%)</td>
</tr>
<tr>
<td>Cytoplasmic</td>
<td>10 (40%)</td>
<td>5 (20%)</td>
<td>5 (20%)</td>
<td>5 (20%)</td>
<td>15/25 (60%)</td>
</tr>
<tr>
<td>Membranous</td>
<td>4 (16%)</td>
<td>5 (20%)</td>
<td>12 (48%)</td>
<td>2 (8%)</td>
<td>14/25 (56%)</td>
</tr>
<tr>
<td><strong>Claudin-1, liver metastasis (n = 12)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nucleus</td>
<td>5 (40%)</td>
<td>2 (16%)</td>
<td>2 (16%)</td>
<td>3 (25%)</td>
<td>7/12 (58%)</td>
</tr>
<tr>
<td>Cytoplasmic</td>
<td>2 (16%)</td>
<td>8 (66%)</td>
<td>1 (8%)</td>
<td>2 (16%)</td>
<td>10/12 (83%)</td>
</tr>
<tr>
<td>Membranous</td>
<td>7 (58%)</td>
<td>4 (33%)</td>
<td>1 (8%)</td>
<td>0</td>
<td>5/12 (42%)</td>
</tr>
<tr>
<td><strong>Claudin-1, lymph node metastasis (n = 13)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nucleus</td>
<td>10 (76%)</td>
<td>1 (8%)</td>
<td>2 (16%)</td>
<td>0</td>
<td>3/13 (23%)</td>
</tr>
<tr>
<td>Cytoplasmic</td>
<td>8 (61%)</td>
<td>3 (23%)</td>
<td>1 (8%)</td>
<td>1 (8%)</td>
<td>5/13 (38%)</td>
</tr>
<tr>
<td>Membranous</td>
<td>7 (54%)</td>
<td>5 (38%)</td>
<td>1 (8%)</td>
<td>0</td>
<td>4/13 (31%)</td>
</tr>
</tbody>
</table>

1+, cytoplasmic: relatively weak, patchy staining, <25% tumor cells; membranous: continuous staining, <50% of cells; nuclear: <25% of tumor cells. 2+: cytoplasmic: staining in 25–50% of cells; membranous: discontinuous staining, 50–75% of cells; nuclear: 25–50% of cells. 3+, cytoplasmic: strong, diffuse staining, >50% of cells; membranous: continuous basolateral staining, >75% of cells; nuclear: >50% of cells. Claudin-1 staining increases with metastasis in patient samples. Immunohistochemistry of 25 patients with matched normal, primary, and lymph node or liver metastatic lesions are shown. A significant linear association between claudin-1 nuclear, cytoplasmic, or membranous staining and tumor progression is demonstrated using a contingency table approach with \( \chi^2 \) approximation: nuclear [Pearson \( \chi^2(3) = 22.44, P < 0.0001 \)], cytoplasmic [Pearson \( \chi^2(3) = 30.23, P < 0.0001 \)], and membranous [Pearson \( \chi^2(3) = 9.51, P < 0.05 \)].
appearing adjacent intestinal epithelium of the ApcMin/+ mice, the claudin-1 immunoreactivity was detected exclusively in cell membrane and a small portion in the cytoplasm (Figure 1R). This observation further supports the notion that nuclear and cytoplasmic localization of claudin-1 is a common event in colorectal tumorigenesis and is associated with loss of APC tumor suppressor function with activation of nuclear β-catenin.

**Claudin-1 is important for tumorigenesis and invasive properties of colon epithelial cells.** To determine whether claudin-1 protein expression has a causal role in tumor progression and invasion, we manipulated the expression levels of claudin-1 expression in SW480 and SW620 cell lines. These cell lines were chosen because they are derived from primary (SW480) and metastatic lesions (SW620) of a single colon cancer patient (28). Since SW480 cells express lower levels of claudin-1 than do SW620 cells, we overexpressed claudin-1 in SW480 cells to achieve claudin-1 levels comparable to the level in SW620 cells. Three such SW480 clones were selected:
SW480claudin-1, -2, and -3 (Figure 2A). The SW480claudin-1 cell morphology appeared spindly and fibroblastoid in monolayer culture, whereas the SW480control showed epithelioid spreading similar to that of parental cells (Figure 2B). Expression of mesenchymal markers vimentin and fibroblast-specific protein–1 (FSP1) (29) and the epithelial marker, E-cadherin, was examined by Western blot and by immunofluorescence analyses. Increased expression of vimentin and FSP1 was observed in SW480claudin-1 compared with the SW480control cells (Figure 2, A and C). The steady-state levels of E-cadherin were not significantly altered (data not shown); however, the localization of E-cadherin was altered in the SW480claudin-1 cells, where we observed it in the cytoplasm and in clustered locations at the cell membrane; in contrast, in SW480control cells, membrane staining was typically diffuse (Figure 2C). β-Catenin was primarily localized at the cell membrane in SW480control cells but was largely cytosolic in the SW480claudin-1 cells (Figure 2C). In addition, the SW480claudin-1 cells formed significantly more colonies in soft agar than did control cells, which indicates enhanced anchorage independence (Figure 2D). Claudin-1 is known to affect MMP activation (25); therefore, we determined whether there were any changes in MMP activation in SW480claudin-1 clones compared with the control cells (Figure 2E).
blot analysis, were selected for further study. No apparent change in claudin-1 protein expression was observed in SW620<sub>control</sub> cells. Also, expression of claudin-4 was not affected in the SW620<sub>siRNA</sub> cells, which validated the specificity of the siRNA (Figure 3A).

Western blot and immunofluorescence analyses indicated a decrease in the expression of mesenchymal markers such as vimentin and FSP1 but a robust increase in E-cadherin expression (Figure 3, A and B) in all 3 SW620<sub>siRNA</sub> clones compared with control cells. Immunofluorescence studies revealed a honeycomb pattern of E-cadherin at sites of cell-cell contact in all SW620<sub>siRNA</sub> clones. In addition, localization of β-catenin increased in the membrane of SW620<sub>siRNA</sub> cells as compared to cytoplasmic and nuclear localization in parental or control cells (Figure 3B and Supplemental Figure 2). Parental and SW620<sub>control</sub> cells exhibited round, elongated, and dispersed morphology, whereas SW620<sub>siRNA</sub> cells exhibited a spreading, epithelial appearance and tended to form multicellular aggregates (Figure 3C). A monolayer wound-healing assay revealed almost no migration in SW620<sub>siRNA</sub> cells compared with SW620<sub>control</sub> cells (Figure 3D). The 3 clones of the SW620<sub>siRNA</sub> cells performed identically in this assay (data not shown for clones 2 and 3).

**Figure 3**
Effects of siRNA-based inhibition of claudin-1 expression in the metastatic SW620 cells. (A) Western blot analysis of SW620 cells stably expressing claudin-1 siRNA (SW620<sub>siRNA</sub>). Equal amounts of total protein were subjected to immunoblot analysis using anti–claudin-1 antibody. The clones shown were selected based on similar levels of inhibition of claudin-1 expressions. The same lysates were also subjected to immunoblot analysis for claudin-4 to determine the specificity of the siRNA oligonucleotide. Immunoblotting for vimentin, FSP1, and E-cadherin was performed using the same lysates. (B) The upper panel represents immunofluorescence localization of claudin-1, β-catenin, E-cadherin, and vimentin in SW620<sub>siRNA</sub> cells. Only SW620<sub>control</sub> cells are shown, as there were no visible differences between SW620<sub>control</sub> cells and parental SW620 cells. The lower panel represents results of immunoblot analysis using cytosolic and membrane-specific fractions for expressions of β-catenin and E-cadherin in SW620<sub>control</sub> and SW620<sub>siRNA</sub> cells. (C) Representative phase-contrast images of monolayer cultures of SW620<sub>control</sub> and SW620<sub>siRNA</sub> cells. (D) Representative photomicrographs of cell migration by monolayer wound-healing assay using SW620<sub>control</sub> and SW620<sub>siRNA</sub> clones. Photomicrographs were obtained 0, 24, 48, and 72 hours after standard scrape wounding, as described in Methods.
The number of soft agar colonies presented is the mean of colony counts from 3 different experiments. (B) A cell invasion assay was performed using 24-well transwells coated with collagen type I (100 µg/ml). After 72 hours of plating, cells from the top of the filter were removed, and the cells that invaded the coated membrane were fixed and counted. Data are presented as mean colony counts in ten ×20 microscopic fields from duplicate wells. *P < 0.05, as compared to control. (C) Gelatin zymography to determine the activities of MMP-2 and MMP-9 in SW620 control and all 3 SW620 siRNA clones was performed as described in the Methods. (D) Cellular proliferation was measured in SW620 control and SW620 siRNA cells using MTT assay at 1, 3, 5, and 7 days after plating equal number of cells. (E) The anoikis assay was performed by plating the SW620 control and SW620 siRNA cells on polyHEMA-coated culture dishes for 72 hours as described in Methods. Values for control cells were considered 100%, and any differences are expressed relative to that value. Each bar represents the mean ± SD of 3 experiments. (F) The anoikis-induced apoptosis was quantitated using apoptosis-specific ELISA. Values for control cells were considered 100%, and any changes were compared with that value. Each bar represents the mean ± SD of 3 experiments.

*P < 0.05; Figure 4A). In addition, using a Boyden chamber invasion assay, we observed a significant decrease in the invasive capacity of SW620 siRNA cells (Figure 4B). A gelatin zymogram for MMP activation demonstrated a decrease in MMP-9 activity in SW620 siRNA compared with SW620 control cells (Figure 4C). However, we did not observe a significant decrease in MMP-2 activity.

Given the importance of induction of proliferation and/or inhibition of apoptosis in the regulation of neoplastic transformation, we investigated the effect of inhibition of claudin-1 expression in SW620 cells on the rate of cellular proliferation. Manual cell counting every 48 hours over a period of 7 days (on days 1, 3, 5, and 7) following plating of equal numbers of cells (data not shown) or tetrazolium salt (MTT) assay (Figure 4D) did not reveal any significant difference in cellular proliferation due to inhibition of claudin-1 expression. Anoikis (apoptosis resulting from loss of cell matrix interaction) is an established model for determining cell survival independent of cell attachment; therefore, we next determined the effect of inhibition of claudin-1 on anoikis. Interestingly, inhibition of claudin-1 in SW620 cells resulted in significant cell death due to anoikis (Figure 4E). To further confirm that the cell death is due to anoikis (Figure 4F).
Conversely, SW620 parental and SW620 was only 20% in mice injected with SW480 cells compared with 80% inhibition of claudin-1 expression significantly increased apoptosis due to anoikis. In contrast, SW480 cells were more resistant than SW480 parental cells to anoikis (data not shown).

Taken together, the above data strongly suggest that claudin-1 plays an important role in the regulation of cellular transformation and thus potentially contributes to the phenotype of invasion and metastasis.

In vivo assessment of tumor growth and metastatic potential. Based on our cell culture data, we postulated that claudin-1 expression would affect tumor formation and metastasis in vivo. Cells from each group (SW480#control and 2 independent clones of SW480#claudin-1 or SW620 parental, SW620#control, and 2 independent clones of SW620#siRNA cells) were injected subcutaneously into the flanks of nude mice (n = 5 for each group). In mice injected with the 2 clones of SW480#claudin-1 cells, measurable tumors appeared within 1 week and grew to an average volume of 233 and 500 mm$^3$, respectively, for 4 weeks after injection. In contrast, tumors from mice injected with SW480#control cells became detectable only after 3 weeks of growth, and the average tumor volume was only 25 mm$^3$ at 4 weeks after injection. Furthermore, the incidence of tumor formation following subcutaneous injections was only 20% in mice injected with SW480 cells compared with 80% in mice receiving claudin-1–overexpressing SW480-derived clones. Conversely, SW620 parental and SW620#control cells started developing tumors at 1–2 weeks after injection, and the average tumor volume was 106 and 114 mm$^3$, respectively, after 4 weeks of growth, while the 2 clones of SW620#siRNA cells had average volumes of 11 and 14.8 mm$^3$, respectively, after the same period of time (Figure 5A).

In order to determine the impact of claudin-1 expression on metastatic potential, we injected nude mice intrasplenically with either SW480#control or SW480#claudin-1 cells or, alternatively, with SW620 parental, SW620#control, or SW620#siRNA cells. We screened mice for liver lesions using microPET imaging starting at 4 weeks after splenic injection, and thereafter screening was repeated weekly. After 4 weeks, mice inoculated with SW480#control cells had 0% incidence of liver metastasis (n = 4; Figure 5B), while the 2 SW480 clones overexpressing claudin-1 had 100% incidence of liver metastasis (n = 4 and 3, respectively; Figure 5, C–E). Large tumor foci on the liver surface were observed in livers of mice injected with SW480#claudin-1 cells, while there were none in the control group (Table 2). Furthermore, histological examination of liver sections from left lobes of each liver confirmed intrahepatic metastatic tumors only in mice injected with SW480#claudin-1 cells (Figure 5, F and G). On the other hand, at 7 weeks after injection, microPET imaging indicated metabolically active abdominal foci in several mice inoculated with SW620 cells (Figure 5, H and I). All of the mice were then euthanized and subjected to autopsy, and surface liver metastases were assessed (Figure 5, J and K). Incidence of liver metastases was detectable in 5 of 5 and 4 of 4 (100%) of parental SW620 and SW620#control groups, respectively, whereas 2 of 4, 2 of 4, and 1 of 5 mice from the 3 SW620#siRNA clones, respectively, had detectable liver metastases. Furthermore, the number of surface tumor foci in livers of mice injected with SW620#siRNA cells was significantly reduced compared with that in the control group (Table 3).

Claudin-1 regulates E-cadherin expression. We observed that inhibition of claudin-1 expression in SW620 cells increases E-cadherin expression. To determine whether claudin-1 regulates E-cadherin protein or mRNA expression, we prepared total RNA from parental, SW620#control, and SW620#siRNA cells and subjected it to semiquantitative RT-PCR analysis as described in Methods. We found that claudin-1 inhibition increased E-cadherin mRNA expression in all 3 clones compared with parental and control transfected cells (Figure 6A). To further determine whether inhibition of claudin-1 expression alters E-cadherin promoter activity, we performed luciferase reporter assays using E-cadherin promoter elements Ecad3/Luc and Ecad5/Luc (containing 1,484 and 493 bp, respectively). Reporter gene constructs containing as few as 493 bp of E-cadherin proximal promoter sequence exhibited a 2.5- to 6-fold increase in E-cadherin promoter activity in SW620#siRNA cells compared with control transfected cells (Figure 6B).

To further explore the mechanism of increased E-cadherin transcription, we examined the mRNA expression of Snail and Slug, which are known to be involved in transcriptional repression of the E-cadherin gene (30–32). Interestingly, mRNA expression levels of Snail or Slug were not affected in SW620#siRNA cells compared with parental or control cells (Figure 6C).

Inhibition of claudin-1 in SW620 metastatic cells leads to a reduction in β-catenin/Tcf/Lef signaling. Previous studies using SW480 colorectal cancer cells demonstrated that E-cadherin mediates inhibition of β-catenin/Tcf/Lef signaling and acts as a tumor suppressor (5, 33). Since inhibition of claudin-1 expression in SW620 cells resulted in a robust increase in E-cadherin expression, this prompted us to investigate whether or not the β-catenin/Tcf/Lef signaling pathway is also inhibited in SW620#siRNA cells. To explore this possibility, we analyzed β-catenin/Tcf/Lef signaling in SW620#control and SW620#siRNA clones as well as SW480#control and SW480#claudin-1 cells using Tcf and mutant Tcf reporter plasmids (TOPflash and FOPflash, respectively) Tcf/Lef luciferase reporter constructs, a well-established assay for measuring transcriptional activation due to activated β-catenin signaling. Briefly, SW480#claudin-1 and SW620#siRNA cell lines and their respective control cells were transfected with plasmids encoding multimerized wild-type (TOP) or mutant (FOP) Lef binding sites followed by a luciferase reporter gene. To control for transfection efficiency, we cotransfected a SV40-driven expression vector.
β-galactosidase with reporter constructs. Relative luciferase activities were calculated as described in Methods. As shown in Figure 6D (upper panel), the relative transcriptional activity of the β-catenin/Lef complex was induced (2- to 4-fold) in SW480claudin-1 cells compared with SW480control cells, whereas it decreased (4- to 5-fold) in SW620siRNA cells compared with SW620control cells.

To further determine the effects of changes in β-catenin activity due to claudin-1 manipulations, we examined the levels of expressed β-catenin/Tcf signaling. Interestingly, RIE and HCT116 cells express wild-type APC (35), but neither cell line expresses detectable levels of claudin-1, despite the presence of a mutation in HCT116 cells that results in β-catenin stabilization. These results imply that there are other mechanisms underlying the silencing of claudin-1 in HCT116 cells and that β-catenin/Tcf activation alone is insufficient to activate expression of the claudin-1 gene. Our studies have not excluded the possibility that an intact
APC protein could regulate the expression of claudin-1 independently of the β-catenin/Tcf pathway.

The observation of increased claudin-1 expression and subcellular localization to the cytoplasm and nucleus in neoplastic tissues is further supported by our findings in adenomas of ApcMin/+ mice. As mentioned before, Min adenomas are known to express mutant APC due to somatic inactivation of the second allele. Histologically normal intestinal epithelium of heterozygous ApcMin/+ mice expresses wild-type APC protein and expresses a normal pattern of claudin-1 protein that is predominantly localized on cell membrane, with a small portion in the cytoplasm. These observations support the conclusion that regulation of claudin-1 expression is an important role of APC; whether this occurs as a consequence of APC regulation of β-catenin/Tcf activation or by another, more direct mechanism remains to be determined.

An important finding of our study was the nuclear localization of claudin-1 in a significant subset of colon cancer samples, particularly among the subset of liver metastatic lesions. Nuclear localization of several cell junction proteins (β-catenin, ZO-1, ZO-2) is known to be correlated with oncogenic transformation and cell proliferation (36, 37). β-Catenin, a component of AJs, plays a well-characterized dual role in cell adhesion (membrane localized) and in signal transduction (cytoplasmic and nuclear) leading to epithelial cell transformation. Further, mutants of the TJ protein ZO-1 that no longer localize at the plasma membrane induce a dramatic epithelial-mesenchymal transition (EMT) of Madin-Darby canine kidney I cells (38). The nuclear localization of claudin-1 in our study was confirmed by several methods. First, 2 distinct antibodies to claudin-1 were used for immunofluorescence and immunohistochemistry studies, respectively, and yielded similar results. Additionally, the nuclear and cytoplasmic fractions clearly demonstrate the presence of claudin-1 in nuclear lysates from SW480 and SW620 cells. There was no difference in the molecular weight of claudin-1 protein recognized in nuclear or cytoplasmic fractions, which suggests that this nuclear localization does not involve major cleavage or modification of the protein. However, the question remains: How is this transmembrane protein translocated to the nucleus? Using a nuclear localization software-based analysis (Nuclear Localization Signal database; Columbia University Bioinformatics Center; http://cubic.bioc.columbia.edu/db/NLSdb) of the claudin-1 sequence, we did not detect any putative nuclear localization signal (NLS). Although NLS sequences are the predominant types of nuclear import elements, other sequences such as PDZ domains are known to be important for targeting proteins to the nucleus. One of the potential mechanisms by which claudin-1 could translocate to the nucleus is through binding to ZO-1 or ZO-2, in a manner similar to Armadillo-repeat gene deleted in Velo-cardio-facial syndrome (ARVC), a member of p120 family. Interaction with ZO-2 via its PDZ binding motif results in ARVC translocation to the nucleus (39). Other examples of proteins that translocate to the nucleus independently of NLS include tumor suppressors such as APC and BRCA1 (40–42). Yet another potential mechanism by which claudin-1 could translocate to the nucleus is by using chaperon or other accessory proteins such as importin-β (43, 44). Studies are currently underway in our laboratory to define the mechanism of claudin-1 translocation to the nucleus.

The importance of claudin-1 as a regulator of colon carcinogenesis is apparent from our studies involving in vitro genetic manipulation of claudin-1 in cultured cells and from the in vivo nude mice studies. As mentioned above, although SW480 and SW620 cells share a similar genetic background, SW620 cells form tumors faster than do SW480 cells, and they metastasize, while SW480 cells...
do not (28). These 2 cell lines have differential claudin-1 expression, with much higher levels in the metastasizing SW620 cells. The differential claudin-1 expression may be one of the reasons for functional differences in these cells. Indeed, modulation of claudin-1 in these cells induced complex morphological changes accompanied by changes in EMT markers and other EMT-related functional behaviors, including migration, anoikis, anchorage-independent growth, invasion, and MMP activation. Interestingly, while overexpression of claudin-1 increases activity of both MMP-2 and MMP-9, inhibition of claudin-1 induced a significant decrease only in MMP-9 activity. As mentioned in Results, siRNA-based inhibition of claudin-1 was 80–90%, and it is possible that the remaining claudin-1 was enough to maintain MMP-2 in its active form. Furthermore, SW480 claudin-1 cells formed tumors at a significantly faster rate and caused multiple liver metastases compared with SW480 control cells, which did not cause any liver metastases. In contrast, the xenograft tumor formation and metastatic ability of SW620 claudin-1 cells was significantly decreased compared with that of SW620 control cells in nude mice. However, it remains to be determined which individual or combinations of specific downstream consequences of high levels of claudin-1 are primarily responsible for the metastatic phenotype.

Our observations that E-cadherin transcription increased along with decreased expression of mesenchymal markers and characteristics after inhibition of claudin-1 expression are consistent with data showing that loss of E-cadherin consistently occurs at sites of EMT during development and in cancer. This loss contributes to tumor cell invasiveness in vitro and promotes transition of adenoma to carcinoma in animal models (45). E-cadherin is known to be regulated at the transcriptional level by the zinc finger transcription factors, Snail and Slug. Both of these transcription factors repress expression of E-cadherin (30–32). However, neither Snail nor Slug mRNA expression is altered in SW620 siRNA cells. Recent studies have demonstrated that changes in protein phosphorylation and cellular localization of Snail protein are important for its activity (46–48). Currently, we are in the process of analyzing the details of differences in Snail protein expression and/or activity due to manipulation of claudin-1 protein expression.

Although overexpression of claudin-1 in SW480 cells induced a decrease in membrane-localized E-cadherin, there was a simultaneous increase in cytoplasmic E-cadherin that might explain unchanged steady-state levels of E-cadherin expression. Furthermore, SW480 cells express comparatively low levels of E-cadherin, and there is low endogenous expression of claudin-1 in these cells. Therefore, claudin-1–dependent transcriptional regulation of E-cadherin may already be at its threshold in these cells. Studies using other colon cancer cell lines with abundant E-cadherin expression and no claudin-1 expression are currently underway in our laboratory to define this interesting observation. While E-cadherin expression increased, β-catenin/Tcf/lef signaling was significantly inhibited in SW620(RNA) cells. β-Catenin/Tcf/Lef has been implicated in signaling events leading to EMT in vivo during embryonic development and in vitro in epithelial cells (49).

We observed an inverse correlation between β-catenin/Tcf/Lef transcriptional activity and the expression of E-cadherin in the SW620(RNA) cells. Our observations are consistent with previous studies using SW480 colon cancer cells, in which the tumor suppressor activity of E-cadherin was shown to be due to inhibition of the β-catenin/Tcf signaling pathway, and suggest that loss of E-cadherin expression results in upregulation of β-catenin/Tcf signaling pathway in human cancers (50). Taken together, these data suggest that both the modulation of β-catenin/Tcf signaling and E-cadherin expression and localization play important roles in the claudin-1–dependent regulation of EMT. Other mechanisms relevant to claudin-1 overexpression in colon cancer are still under investigation. However, the present observations raise the possibility of exploiting claudin-1 as a potential biomarker for colon cancer progression and might provide new opportunities for therapeutic intervention.

**Methods**

**Plasmids and reagents.** The antibodies against claudin-1, -4, and -7 were obtained from Zymed Laboratories Inc. Actin and vimentin antibodies were purchased from Sigma-Aldrich. Anti–β-catenin and –E-cadherin antibodies were purchased from BD Biosciences – Transduction Laboratories. Anti-c-Myc antibody was purchased from Santa Cruz Biotechnology Inc. Luciferase reporter constructs containing E-cadherin 5′ flanking sequence were generously provided by Eric Fearon (University of Michigan, Ann Arbor, Michigan, USA) (Ecad 3 [1,484 bp] and Ecad 5 [493 bp]) (51). The siRNA cassettes were synthesized by GenScript Corp. and contained siRNA oligonucleotide against human claudin-1 (CATCTTCATCAATATGGAA) downstream of U6 promoter with custom restriction sites (BamHI and MluI), which were used for subcloning into pRNA-neo for stable transfections. A control siRNA oligonucleotide, which does not match any known human coding cDNA, was used as control. The Le/Tcf reporter plasmid, TOPFlash, and its mutant control, FOPFlash, were purchased from Upstate.

**Cell culture and transfection.** The human colon cancer cell lines HCT116, HT29, SW480, and SW620 and normal RIE cells were obtained from ATCC and cultured in DMEM containing 10% FBS. One day before transfection, the cells were seeded in 6-well cell culture plates to provide a final density of 60–70% confluence. Cells were transfected (52) using Effectene Transfection Reagent (Qiagen) as described previously. We calculated fold stimulation for each sample by dividing the normalized luciferase activity by the value obtained from the control transfection containing empty parental expression vectors (pCMVs). The stable clones were generated using neomycin as selection reagent.

**Immunoblot analysis.** Immunoblotting was done according to our standard protocol, as described previously (53). The signal was visualized with HRP-conjugated secondary antibodies using enhanced chemiluminescence (Pierce).

**Immunohistochemistry and immunofluorescence.** Paraaffin-embedded tumors and normal tissue samples were obtained from colon cancer patients with primary and metastatic disease using protocols approved by the Vanderbilt University Institutional Review Board. Each primary colon cancer specimen was matched with either simultaneous lymph node or liver metastasis from
the same patient. Immunohistochemistry was performed using rabbit anti–claudin-1 antibody as described previously (52). Immunofluorescence was performed using the following primary antibodies: rabbit anti–claudin-1 and -claudin-7, mouse anti–E-cadherin and -β-catenin, and anti-veclinint. Secondary antibodies were either donkey anti-rabbit Rhodamine Red-X or goat anti-mouse FITC (Jackson Immunoresearch Laboratories Inc.). Stained sections were viewed and photographed using a fluorescence microscope.

Nuclear/cytosplasmic/membrane extracts. Confluent colon cancer cells were used for isolation of nuclei and cytoplasmic and membrane fractions as described previously (52). All samples were stored frozen at −80°C until analysis. To ensure no cross-contamination between the fractions, the same membrane was stripped and reprobed with antibodies to α-tubulin (a cytosol-specific protein) or hnRNP70 (a nucleus-specific protein).

RNA isolation and RT-PCR. Total RNA was extracted from colon cancer cells with a QIAGEN RNeasy kit. Full-length claudin-1 cDNA was amplified using primers based on the published human claudin-1 sequence (GenBank accession number AH010563), and was cloned into pCMV-Script Vector (Stratagene) for stable transfections. For semiquantitative RT-PCR analyses, random-primed, first-strand cDNA was generated from 1 μg total RNA (RETROscript Kit; Ambion) per the manufacturer’s recommendation. PCR analysis was performed using gene-specific primers and diluted first-strand cDNA as template. PCR cycles were limited to 25, and primers for actin were used as internal control.

Anchorage-independent growth. A total of 40,000 cells was plated in 1 ml of DMEM with 0.3% low-melting agarose and 10% FBS and overlayed on 1 ml/35 mm dish of DMEM with 0.5% agarose and 10% FBS. After 2 weeks, plates were photographed (×40) and colonies were counted by using the Bio-Rad Gel Doc colony-counting function. The results represent the mean of 3 individual experiments.

Gelatin zymography. Cells were plated at a density of 200,000 in 24-well plates. After 16 hours, cells were washed with PBS and incubated in 300 ml of serum-free medium for 24 hours. Fifty-milliliter aliquots of conditioned medium were diluted in sample buffer (5% SDS), 20% glycerol, 0.4 mol/l Tris, pH 6.8 containing 0.02% bromophenol blue without reducing agent and –claudin-7, mouse anti–E-cadherin and –claudin-1, goat anti-mouse FITC (Jackson Immunoresearch Laboratories Inc.). Stained gels were dried at 50°C for 1 hour, and the same membrane was stripped and reprobed with antibodies to α-tubulin (a cytosol-specific protein) or hnRNP70 (a nucleus-specific protein). The absorbance was measured at 405 nm.

Cell migration and cell culture wound assay. Wounds were created in confluent cells using a pipette tip. The cells were then rinsed with medium to remove any free-floating cells and debris. Serum-free medium was then added, and culture plates were incubated at 37°C. Wound healing was observed at 0, 24, 48, and 72 hours within the scrape line, and representative scrape lines for each cell line were photographed. Duplicate wells of each condition were examined for each experiment, and each experiment was repeated 3 times.

Invasion assay. Transwell filters (8.0 μm) were coated overnight with 100 μg/ml collagen type I (Sigma-Aldrich). Cells were suspended at 100,000 cells per well in 12-well filter plates (Falcon; BD) in serum-free medium. Serum containing medium (0.5%) was utilized as the chemotactrant in the lower chamber. After 72 hours of incubation, cells that had invaded to the lower surface of the collagen-coated membrane were fixed with 70% ethanol, stained with crystal blue, and counted in 5 randomly selected fields under a light microscope. Data are expressed as mean ± SD of 3 individual experiments.

In vivo studies. All animal experiments were conducted with the approval of the Institutional Animal Care and Use Committee (IACUC) of Vanderbilt University. Tumorigenicity was assessed by subcutaneous flank inoculation of 1 × 106 cells in 6-week-old female athymic nude mice, and animals were assessed 4 weeks after inoculation. Five mice were used for each clone.

To assess the impact of overexpression or inhibition of claudin-1 on metastasis in vivo, female athymic nude mice (7 weeks old; n = 5) were injected in the spleen with 5 × 106 cells of either SW480siRNA and SW480claudin-1 cells or SW620 parental, SW620siRNA, and SW620RNA cells. The spleen was removed after tumor cell injection, and a small hemoclip was applied to the splenic vessels. Nude mice in the SW480 group were sacrificed at 4 weeks, and the number and size of metastatic tumor foci on the surface of the livers were documented. For the SW620 group, small-animal microPET imaging was used to screen for nonpalpable lesions in the liver, using 100–150 μCi of 18F-deoxyglucose ([18F]FDG) injected i.p to detect metabolically active foci in the abdomen. When the tumors were visible by microPET (7 weeks), the mice were subjected to autopsy. The number and size of metastatic tumor foci on the surface of the livers were documented.

Statistical analysis. A Student’s t test and 2-sided test of proportions were used to determine statistical significance, and differences were considered statistically significant at P ≤ 0.05. The test for linear association between claudin-1 staining and tumor progression was performed using a contingency table approach with χ2 approximation.

Acknowledgments
This work was supported by NIH grants DK52334 and CA69457 (to R.D. Beauchamp), the Vanderbilt-Ingram Cancer Center Support grant (P30 CA68485), and National Cancer Institute Specialized Programs of Research Excellence Grants in Gastrointestinal Cancer P50 CA95103 and SP50 CA095103 (to P. Dhawan). Received for publication January 21, 2005, and accepted in revised form May 10, 2005.

Address correspondence to: Punita Dhawan, Department of Surgical Oncology, Vanderbilt University Medical Center, D-2300, Medical Center North, 1161 21st Avenue S, Nashville, Tennessee 37232, USA. Phone: (615) 322-4755; Fax: (615) 322-6174; E-mail: punita.dhawan@vanderbilt.edu.